KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Invested Capital (2019 - 2025)

Alnylam Pharmaceuticals' Return on Invested Capital history spans 9 years, with the latest figure at 0.85% for Q4 2025.

  • For Q4 2025, Return on Invested Capital rose 220.0% year-over-year to 0.85%; the TTM value through Dec 2025 reached 0.85%, up 220.0%, while the annual FY2025 figure was 1.03%, 334.0% down from the prior year.
  • Return on Invested Capital reached 0.85% in Q4 2025 per ALNY's latest filing, down from 1.85% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 6.98% in Q4 2022 to a low of 13.29% in Q3 2024.
  • Average Return on Invested Capital over 5 years is 0.15%, with a median of 0.53% recorded in 2022.
  • Peak YoY movement for Return on Invested Capital: plummeted -1455bps in 2024, then soared 1515bps in 2025.
  • A 5-year view of Return on Invested Capital shows it stood at 0.58% in 2021, then soared by 1307bps to 6.98% in 2022, then plummeted by -79bps to 1.48% in 2023, then crashed by -191bps to 1.35% in 2024, then soared by 163bps to 0.85% in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Return on Invested Capital are 0.85% (Q4 2025), 1.85% (Q3 2025), and 0.49% (Q2 2025).